Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2026 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...
January 21, 2026 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...
January 21, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
January 20, 2026 14:13 ET | Source: Forbion

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a...
January 20, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP
January 20, 2026 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System

ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational...
January 20, 2026 07:19 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced...
January 16, 2026 05:00 ET | Source: Nouscom Srl

Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce...
January 15, 2026 17:10 ET | Source: Liberation Bioindustries

Liberation Bioindustries Announces New Roles for Founders

RICHMOND, Ind., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Liberation Bioindustries announces its co-founders have assumed new roles in the company; originally Chief Executive Officer (CEO), Mark Warner is...
January 15, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma’s pancreatic proenzyme formulation known as PRP.